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Abstract
Detection of protein-protein interactions in cells is crucial for understanding the biological 
functions of proteins, including their roles in signal transduction. However, current methods 
require specific antibodies both for immunoprecipitation and detection, making them expensive 
and sometimes unreliable. Here we describe protocols for protein-protein interaction assays that 
use nonimmune IgG-conjugated Sepharose to precipitate the IgG binding domain (ZZ) fused to 
the bait protein; the interaction partner is fused to Avitag and biotinylated by BirA so that it can be 
detected by a one-step blot with Dylight 680 streptavidin to detect the Avitag fusion protein. Since 
this method does not require specific antibodies and is inexpensive, sensitive, and reliable, it 
should be useful for detecting protein-protein interactions in cells.
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Protein-protein interactions contribute to a variety of biological processes, including signal 
transduction, tissue integrity, and force generation (1,2). An inexpensive and reliable method 
to measure protein-protein interactions would be of considerable utility. Currently, co-
immunoprecipitations (Co-IP) are routinely used to detect protein-protein interactions in 
cells, where one antibody is used to isolate the bait proteins and another antibody is used to 
detect the interaction. Since antibodies are expensive reagents, qualities of antibodies change 
from lot to lot, and manufacturer claims may not be true (3), this method is neither 
economical nor reliable. Thus, a technique that does not depend on specific antibodies 
would be useful for protein-protein interactions assays.
Address correspondence to Cai Huang, Markey Cancer Center and Department of Molecular and Biomedical Pharmacology, 
University of Kentucky, Lexington, KY 40506, USA. cai-huang@uky.edu. 
Competing interests The authors declare no competing interests.
To purchase reprints of this article, contact: carmelitag@fosterprinting.com
HHS Public Access
Author manuscript
Biotechniques. Author manuscript; available in PMC 2015 May 22.
Published in final edited form as:













The biotin/avidin (or streptavidin) system has numerous applications in modern biological 
studies because the interaction of biotin with avidin is one of the highest affinity interactions 
known in nature. Recently, the applications of this system have been greatly promoted by 
the discovery of BirA, an Escherichia coli biotin ligase that specifically conjugates biotin to 
a 15-amino-acid Avitag (GLNDIFEAQKIEWHE) (4,5). BirA-mediated biotinylation of 
Avitag fusion proteins has been used in protein purification (6), detection (7,8), and 
fluorescence imaging (9–12). Thus, BirA-mediated biotinylation, which can be easily 
detected by fluorescent streptavidin blot (designated as the Avitag-BirA system), has great 
potential application in detecting interacting Avitag fusion proteins in protein-protein 
interaction assays without using specific antibodies.
For protein-protein interaction assays in cells, a method is needed to isolate bait proteins. 
The ZZ domain, a synthetic IgG binding protein derived from tandem repeats of the B 
domain of protein A, was successfully used to replace protein A in antibody purification 
(13,14). It was also engineered to fuse with many different proteins and expressed as ZZ-
tagged fusion proteins in diversified cell types, ranging from bacterium to mammalian cells 
(15–17). To date, no reports have suggested that the ZZ domain impairs the function of 
proteins fused to it, and ZZ fusion proteins can be easily purified by using IgG-Sepharose. 
Therefore, we proposed a novel method for protein-protein interaction assays in cells, in 
which inexpensive, nonimmune rabbit IgG-conjugated Sepharose beads can be used to 
precipitate the ZZ domain fusion protein (as bait); subsequently, fluorescent streptavidin can 
be used to detect the interacting Avitag protein that was biotinylated by BirA.
In this study, we have examined whether the Avitag-BirA system is useful for in vitro GST 
pulldown assays and whether the Avitag-BirA system, in combination with the ZZ domain 
purification technique (designated as the AviZZ system), can be used for protein-protein 
interaction assays in cells. Generic protocols for in vitro GST pulldown assays and protein-




Chinese hamster ovary (CHO)–K1 cells were from ATCC (Manassas, VA, USA). DMEM/
F-12, FBS, G418, Lipofectamine, and Plus reagents were from Invitrogen (Carlsbad, CA, 
USA). Dylight 680 (DL680)–conjugated streptavidin was from Rockland (Gilbertsville, PA, 
USA). Biotin and CNBr-activated Sepharose 4B were from Sigma-Aldrich (St. Louis, MO, 
USA). pET21a-BirA was from Addgene (Boston, MA, USA; deposited by Alice Ting's lab 
at the Massachusetts Institute of Technology, Cambridge, MA, USA). pEGFP-Git1 and 
pEGFP-PIPKIγ were provided by Mark Ginsberg (University of California at San Diego, 
San Diego, CA, USA). pHM6-Tal1–433 was described previously (18). ImmunoPure 
Immobilized Protein A Plus and DL680 NHS ester were from Pierce (Rockford, IL, USA). 
Mouse paxillin cDNA was from Open Biosystems (Huntsville, AL, USA). Glutathione 
Sepharose and pGEX-6X-1 vector were from GE Heathcare Biosciences (Piscataway, NJ, 
USA). Pfu and Quick-Change mutation kit were from Agilent Technologies (Santa Clara, 
CA, USA). Protease inhibitor cocktail was from Roche Applied Science (Indianapolis, IN, 
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USA). Nonimmune IgG was purified from pre-immune rabbit sera, which was from 
Genemed Synthesis (San Antonio, TX, USA), and conjugated to CNBr-activated Sepharose 
4B according to the manufacturer's protocol.
Plasmid construction
To generate pEGFP-paxillin and pGEX-paxillin, DNA fragments encoding residues 2–557 
of mouse paxillin were amplified by Turbo Pfu-based PCR using paxillin cDNA as template 
and 5′-AAAAAAGAATTCAGACGACCTCGATGCCCTG-3′ and 5′-
AAAAAAGTCGACCTAGCAGAAGAGCTTCACGAAGCA-3′ as primers. The DNA 
fragments were digested with EcoRI and SalI and, respectively, subcloned into pEGFP-C1 
and pGEX-4T-3 vectors predigested with the same enzymes. To create pEGFP-BirA, DNA 
fragments encoding BirA were clipped from pET21a-BirA by EcoRI and XhoI digestion and 
then subcloned into pEGFP C2 that was predigested with EcoRI/SalI. To construct AviTag 




CCATGGTGGCA-3′ were annealed and ligated with the larger fragment of AgeI/ BglII-
digested pEGFP-paxillin. To make pAvi-Git1, the DNA fragments encoding full-length Git1 
were clipped from pEGFPGit1 by EcoRI and SalI digestion and ligated with the larger 
fragment of EcoRI/SalI-digested pAvi-paxillin. To generate Git1 fused with the IgG binding 
domain of protein A (designed as pZZ-Git1), DNA fragments encoding the ZZ domain were 
amplified by Pfu-based PCR using pEZZ18 as the template and 5′-
ATATATACCGGTGCCACCATGGACAACAAATTCAACAAAGAACAACAAAACGC
G-3′/5′-TTAATACTCGAGCTACTTTCGGCGCCTGAGCATCATTTAGC-3′ primers, 
digested with AgeI and XhoI, and then ligated with the larger fragment of AgeI/BglII-
digested pEGFP-Git1. To construct pZZ-PIPKIγ and pAvi-PIPKIγ, DNA fragments 
encoding phosphatidylinositol 4-phosphate 5-kinaseγ (PIPKIγ) were clipped from pEGFP-
PIPKIγ (on pEGFP-C2) by digesting with EcoRI/SalI and were ligated with EcoRI/SalI-
digested pZZ and pAvi vectors (pZZ-Git1 and pAvi-paxillin were digested with EcoRI/SalI 
to remove Git1 and paxillin), respectively. The resultant plasmids are not in-frame and were 
digested with XhoI/HindIII, treated with Klenow, and circularized to become in-frame pZZ-
PIPKIγ and pAvi-PIPKIγ. To create pAvi-TH, DNA fragments encoding residues 2–433 of 
talin were amplified by Pfu-based PCR using talin cDNA as the template and 5′-
TATATAGAATTCGTTGCGCTTTCGCTGAAGATTAGCATTG-3′/5′-
ATATATCTCGAGTTACTGAAGGACTGTTGACTTTTTGGGAGACAC-3′ as primers, 
digested with EcoRI/XhoI, and subcloned into pAvi vector via EcoRI and SalI sites. The 
resultant plasmid was not in-frame and was sequentially digested with EcoRI, treated with 
mung bean nuclease, cut with BglII, treated with Klenow, and circularized to become in-
frame pAvi-TH. To generate pZZ-TH, DNA fragments encoding residues 2–433 of talin 
plus six histidine residues were amplified by Pfu-based PCR using pHM6-tal1–433 as 
template and 5′-ATATATCTCGAGTTGCGCTTTCGCTGAAGATTAGCATTGGG-3′/5′-
TGAGTGGGTACCCTTAATGATGATGATGATGATGCACGTG-3′ as primers, digested 
with XhoI/Kpn1, and subcloned into pZZ vector via XhoI and Kpn1 sites.
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Cell culture and transfection
CHO-K1 cells were maintained in DMEM/F-12 medium containing 10% FBS, 100 U/mL 
penicillin, and 100 μg/mL streptomycin. CHO-K1 cells were transfected with Lipofectamine 
Plus transfection reagent according to the manufacturer's protocol. Cells stably expressing 
EGFP-BirA were obtained by sorting enhanced GFP (EGFP) positive cells after G418 
selection in the University of North Carolina Flow Cytometry Facility (Chapel Hill, NC, 
USA).
Protein interaction
GST pulldown assays—CHO-K1 cells stably expressing EGFP-BirA were transfected 
with Avitag plasmids. At 24 h post-transfection, cells were incubated with 500 μM biotin for 
1 h and then lysed with Lysis Buffer A (50 mM Tris-HCl, pH 7.4, 1% NP40, 150 mM NaCl, 
1 mM EDTA, and protease inhibitor cocktail). The lysates were cleared and incubated with 
glutathione Sepharose beads loaded with GST fusion proteins at 4°C for 2 h. The beads were 
washed with the lysis buffer four times and were resuspended in SDS sample buffer. 
Samples were analyzed by SDS-PAGE and transferred to a nitrocellulose membrane. The 
membrane was blocked with 5% nonfat milk in TBST buffer (10 mM Tris-HCl pH 7.5, 140 
mM NaCl, 0.1% Tween 20) for 1 h, rinsed twice with TBST buffer, and then blotted with 
DL680-streptavidin (1:10,000) in TBST buffer containing 5% BSA for 1 h. The membrane 
was scanned with an Odyssey Infrared Imaging System (LI-COR Bioscience, Lincoln, NE, 
USA).
Coprecipitation assays in cells—CHO-K1 cells stably expressing EGFP-BirA were 
transfected with a plasmid carrying a ZZ domain fusion protein and another plasmid 
encoding an Avitag fusion protein. At 24 h post-transfection, cells were incubated with 500 
μM biotin for 1 h and then lysed with Lysis Buffer A. The lysates were cleared and 
incubated with rabbit IgG-Sepharose beads at 4°C for 2 h to precipitate the ZZ domain 
fusion protein. The beads were washed and analyzed by SDS-PAGE and Western blot as 
above. The Avitag protein that bound the ZZ domain fusion protein was detected with 
DL680-streptavidin, while the expression of the ZZ domain fusion protein was probed with 
DL680-rabbit IgG.
Results and discussion
To test whether the Avitag-BirA system would be feasible for in vitro GST pulldown assays 
(protocol depicted in Figure 1A), CHO-K1 cells stably expressing EGFP-BirA (CHOB 
cells) were transfected with pAvi-type I PIPKIγ, a talin-binding protein (19,20). At 24 h 
post-transfection, Avi-PIPKIγ was labeled with biotin by incubating the cells with biotin. 
Then we examined the binding of the biotinylated Avi-PIPKIγ expressed in CHO cells to 
GST-tal210-605, a talin fragment, and detected with DL680-labeled streptavidin. As shown 
in Figure 2A, the talin fragment GST-Tal210-605 strongly interacted with PIPKIγ, whereas 
GST-profilin had no association with PIPKIγ. The interaction of GST-paxillin with Git1, a 
paxillin binding protein (21), was also used to examine the performance of this method. 
Streptavidin-recognizing bands were detected in Avi-Git1-transfected cells but not in mock-
transfected cells (Figure 2B), indicating that streptavidin specifically recognizes biotinylated 
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Git1. Git1 bound paxillin, whereas profilin had no interaction with paxillin (Figure 2B). 
These results indicate that streptavidin can be used in conjunction with Avitag and BirA to 
replace antibodies when detecting protein-protein interactions in GST pulldown assays.
To compare the sensitivities between the Avitag-BirA system and conventional antibody 
detection, CHOB cells were transfected with Avi-PIPKIγ. The cells were treated with biotin, 
and the expression of Avi-PIPKIγ was detected by blotting with an anti-PIPKIγ antibody 
and DL680-streptavidin, respectively. As shown in Figure 2C, the Avitag-BirA system was 
approximately twice as sensitive as the anti-HA antibody detection. Three epitope tag 
antibodies including two anti-HA antibodies and one anti-GFP antibody were also compared 
with the Avitag-BirA system (data not shown). The Avitag-BirA system was significantly 
more sensitive than the conventional antibody detection, ranging from 1- to 18-fold.
Next, we tested whether the AviZZ system (protocol depicted in Figure 1B) could be used 
for protein-protein interaction assays in cells. Before we evaluated the full AviZZ system, 
we needed to test whether nonimmune IgG could be used to precipitate the ZZ-domain 
fusion protein (as bait) from cell lysates. To generate ZZ-PIPKIγ, DNA fragments encoding 
a 7-kDa, single copy of the tandem repeat sequence of the B domain of protein A (ZZ 
domain) were inserted at the N terminus of PIPKIγ. CHO-K1 cells were transfected with 
ZZ-PIPKIγ, and ZZ-PIPKIγ in lysates was precipitated by incubating with nonimmune 
rabbit IgG-conjugated Sepharose. As shown in Figure 3, A and B, ZZ-PIPKIγ was purified 
and efficiently enriched approximately 80-fold after IgG-Sepharose affinity pulldown. ZZ-
tagged proteins were enriched 36-fold, on average, in precipitation assays using IgG-
Sepharose. This efficiency is comparable to or better than antibodies commonly used for 
immunoprecipitation. Thus, nonimmune IgG-conjugated Sepharose can be used to isolate 
ZZ-tagged bait proteins in protein-protein interaction assays.
Next we asked whether DL680-streptavidin could be used to detect biotinylated Avitag 
proteins that bind the bait protein isolated by IgG-conjugated Sepharose. To this end, CHO-
K1 cells that stably express BirA were transfected with Avi-PIPKIγ with or without ZZ-talin 
head (ZZ-TH), as indicated (Figure 4A). The cells were incubated with biotin to label Avi-
PIPKIγ, and ZZ-TH was precipitated with IgG-Sepharose. The binding of Avi-PIPKIγ to 
ZZ-TH was detected using DL680-streptavidin. ZZ-TH strongly coprecipitated with Avi-
PIPKIγ, whereas Avi-PIPKIγ was not detected when empty vector was transfected instead 
of ZZ-TH (Figure 4A, lane 1) or when IgG-Sepharose was replaced with Sepharose alone 
for isolation (Figure 4A, lane 4). Cotransfection of ZZ- PIPKIγ and Avi-TH also generated 
similar results (Figure 4B).
We further examined this method by testing the coprecipitation of paxillin and Git1. CHOB 
cells were transfected with Avi-paxillin with or without ZZ-Git1 cotransfection, as indicated 
(Figure 4C). The interaction of Avi-paxillin to ZZ-Git1 was analyzed and detected by using 
Dylight680 streptavidin as described above. ZZ-Git1 bound Avi-paxillin, except in cases 
where ZZ-Git1 was not expressed (Figure 4C, lane 1), or Sepharose was used in the 
precipitation (Figure 4C, lane 4). Thus, Avitag, in combination with BirA and the ZZ 
domain (designated as AviZZ system), constitutes an inexpensive and sensitive method for 
protein-protein interaction assays in cells.
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Finally, we compared the efficiency of the AviZZ system to that of the conventional Co-IP 
for protein-protein interaction assays. CHOB cells were transfected with Avi-TH plus wild-
type (WT) ZZ-PIPKIγ or Avi-TH plus ZZ-PIPKIγ W647F, a mutant that is deficient in talin 
binding; PIPKIγ WT and the mutant were precipitated with IgG-Sepharose, and the 
interaction of TH with PIPKIγ was detected with DL680-streptavidin. At the same time, 
CHO-K1 cells were transfected with His-tagged TH plus EGFP-PIPKIγ WT or His-tagged 
TH plus EGFP-paxillin (as a control), and His-tagged TH was precipitated with an anti-
polyHis monoclonal antibody; the interaction of PIPKIγ with TH was detected with an anti-
GFP polyclonal antibody. As shown in Figure 4D, the interaction reflected by the blots 
detected by the AviZZ system was >5-fold stronger than that detected by the conventional 
immunoprecipitation. Several other commercial antibodies were also tested for Co-IP, but 
these antibodies were unable to precipitate any proteins, even though the manufacturers 
claimed that they could be used for immunoprecipitation. The higher efficiency of the 
AviZZ system is probably due to both the high efficiency of the ZZ-tagged protein 
precipitation by nonimmune IgG and the high sensitivity of the Avitag-BirA system.
The AviZZ system uses low-cost nonimmune IgG for precipitation and fluorescent 
streptavidin for one-step detection, whereas conventional immunoprecipitation assays 
require expensive specific antibodies for both precipitation and detection. Also, the 
nonimmune IgG provides efficient precipitation of the ZZ domain fusion proteins, while 
many commercial antibodies are not efficient for immunoprecipitation, and the quality of 
specific antibodies is variable (3). Furthermore, the AviZZ system is more sensitive than 
conventional antibody/antigen-based detection, because of the high affinity of the biotin-
streptavidin interaction. The system can be easily adapted for other applications, such as 
ubiquitination assays. This method requires protein overexpression and therefore cannot be 
used for endogenous protein-protein interaction studies. Another drawback is that the ZZ 
domain (7 kDa) is larger than most other epitope tags. That said, the AviZZ system provides 
a low-cost, reliable, and sensitive method for protein-protein interaction assays in cells.
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Figure 1. Scheme depicting the principle of protein-protein interaction assays using the Avitag-
BirA system
(A) CHOB cells were transfected with a plasmid encoding an Avitag protein. After biotin 
treatment, the Avitag protein was biotinylated by BirA. The cells were lysed, and the Avitag 
protein in cell lysates was pulled down with glutathione Sepharose preloaded with a GST 
fusion protein. After SDS-PAGE and Western blotting, the interaction of the biotinylated 
Avitag protein with the GST fusion protein was detected in one step by blotting with 
DL680-streptavidin. (B) A plasmid encoding a ZZ domain fusion protein was cotransfected 
with a plasmid expressing an interacting Avitag protein into CHOB cells. After biotin 
treatment, the Avitag protein was biotinylated by BirA. The cells were lysed, and the ZZ 
domain fusion protein in cell lysates was precipitated with IgG-Sepharose. After SDS-
PAGE and Western blotting, the interaction of the biotinylated Avitag protein with the ZZ 
domain fusion protein was detected in one step by blotting with DL680-streptavidin.
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Figure 2. PIPKIγ-talin and paxillin-Git1 interactions were used to examine the potential of the 
Avitag-BirA system for in vitro GST pulldown assays
(A) PIPKIγ pulldown with a GST talin mutant. CHOB cells were transfected with Avi-
PIPKIγ and treated with biotin. The lysates were incubated GST-profilin or GST-Tal210–
605 immobilized on glutathione Sepharose beads. The Avi-PIPKIγ binding was detected by 
blotting with DL680-streptavidin. (B) Git1 pulldown with GST-paxillin. The CHOB cells 
were transfected with Avi-Git1 or empty vector and treated with biotin. The lysates were 
incubated GST-profilin or GST-paxillin immobilized on glutathione Sepharose beads. The 
Avi-Git1 binding was detected by blotting with DL680-streptavidin. (C) Sensitivity 
comparison between the Avitag-BirA system and the conventional antigen/antibody 
detection. The CHOB cells were transfected with Avi-PIPKI and treated with biotin. Cell 
lysates were applied to SDS-PAGE and Western blotting, and Avi-PIPKIγ was detected by 
an anti-PIPKIγ polyclonal antibody and DL680-streptavidin, respectively. Densities of 
protein bands were measured using ImageJ as described previously (18); the relative 
densities are shown on the top of the figure.
Huang and Jacobson Page 9













Figure 3. Precipitation and enrichment of ZZ domain fusion proteins by IgG-Sepharose
(A) ZZ-PIPKIγ was used to test the feasibility of IgG-Sepharose for precipitation. CHO-K1 
cells were transfected with ZZ-PIPKIγ, and cell lysates were incubated with Sepharose (lane 
1) or IgG-Sepharose (IgGSeph) beads (lane 3). The beads were washed and analyzed with 
SDS-PAGE. IgG-Sepharose beads that were not incubated with cell lysate were run as a 
control. Leaky protein bands from IgG-Sepharose are shown in lanes 2 and 3. (B) IgG-
Sepharose enriches ZZ-PIPKIγ from cell lysates. Cell lysates containing ZZ-PIPKIγ were 
incubated with IgG-Sepharose (lane 1) and Sepharose beads alone (lane 2). The beads were 
washed, and ZZ-PIPKIγ bound on the beads was detected by probing with DL680-
streptavidin after SDS-PAGE and Western blotting. Cell lysates (1.25%) used in lane 1 and 
lane 2 were shown in lane 3 and lane 4, respectively. Lane 1 shows that considerable 
enrichment from lysates is achieved.
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Figure 4. PIPKIγ-TH and Paxillin-Git1 interactions were used to examine the potential of the 
AviZZ system for protein-protein interaction assays in cells
(A) The AviZZ system was examined by testing the coprecipitation of Avi-PIPKIγ and ZZ-
TH. ZZ-TH was cotransfected with Avi-PIPKIγ or empty vector into CHOB cells as 
indicated. After biotin treatment, ZZ-TH was precipitated with IgG-Sepharose (lanes 1–3) or 
Sepharose beads (lane 4). The beads were analyzed by SDS-PAGE and Western blotting. 
The interaction of Avi-PIPKIγ with TH was detected by blotting with DL680-streptavidin 
(upper panel). ZZ-TH precipitated by IgG-Sepharose was detected with DL680-conjugated 
nonimmune IgG (middle panel), and the expression of Avi-PIPKIγ in cell lysates was 
probed with DL680-streptavidin (lower panel). (B) The AviZZ system was examined by 
testing the coprecipitation of Avi-TH and ZZ-PIPKIγ. ZZ-PIPKIγ was cotransfected with 
Avi-TH or empty vector into CHOB cells as indicated. After biotin treatment, ZZ-PIPKIγ 
was precipitated with IgG-Sepharose (lanes 1–3) or Sepharose (lane 4). (C) The generality 
of AviZZ system was further investigated by testing the coprecipitation of Avi-paxillin and 
ZZ-Git1 in CHOB cells as described in panel A. (D) The efficiency of the AviZZ system 
compared with that of the conventional co-immunoprecipitation assays. Upper panel, co-
precipitation of Avi-TH and ZZ-PIPKIγ by using the AviZZ system. The experiment was 
performed as described in panel B. Lower panel, co-immunoprecipitation of His-TH and 
EGFP-PIPKIγ. His-TH (pHM6-Tal1–433, expressing talin head with HA and His double 
tags) was cotransfected with EGFPPIPKIγ or EGFP-paxillin (as a control) into CHO-K1 
cells as indicated. His-TH was immunoprecipitated with an anti-polyHis monoclonal 
antibody. The interaction of EGFP-PIPKIγ with His-TH was detected by blotting with an 
anti-GFP polyclonal antibody.
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